Phenotypes associated with this allele

• Allele Symbol: Stk3^tm1.1Yy
• Allele Name: targeted mutation 1.1, Yingzi Yang
• Allele ID: MGI:4422170
• Summary: 8 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Stk3^tm1.1Yy/Stk3^tm1.1Yy	involves: C57BL/6 * CBA	MGI:4422178
cn2	Stk3^tm1.1Yy/Stk3^tm1Yy Stk4^tm1.1Yy/Stk4^tm1.1Yy	involves: C57BL/6 * CBA	MGI:4422182
cn3	Stk3^tm1.1Yy/Stk3^tm1Yy Stk4^tm1.1Yy/Stk4^tm1.1Yy Tg(CAG-cre/Esr1*)5Amc/0	involves: C57BL/6 * CBA	MGI:4422186
cn4	Stk3^tm1.1Yy/Stk3^tm1Yy Stk4^tm1.1Yy/Stk4^tm1.1Yy Speer6-ps1^Tg(Alb-cre)21Mgn/Speer6-ps1^+	involves: C57BL/6 * CBA * DBA	MGI:4422187
cn5	Stk3^tm1Yy/Stk3^tm1.1Yy Stk4^tm1.1Yy/Stk4^tm1.1Yy Tg(Prrx1-cre)1Cjt/0	involves: C57BL/6 * CBA * SJL	MGI:4422181
cx6	Stk3^tm1.1Yy/Stk3^tm1.1Yy Stk4^tm1.1Yy/Stk4^tm1.1Yy	involves: C57BL/6 * CBA	MGI:4422180
cx7	Stk3^tm1.1Yy/Stk3^tm1Yy Stk4^tm1.1Yy/Stk4^tm1.1Yy	involves: C57BL/6 * CBA	MGI:4422183
cx8	Stk3^tm1.1Yy/Stk3^+ Stk4^tm1.1Yy/Stk4^tm1.1Yy	involves: C57BL/6 * CBA	MGI:4422185

Genotype
MGI:4422178

hm1

• Allelic Composition: Stk3^tm1.1Yy/Stk3^tm1.1Yy
• Genetic Background: involves: C57BL/6 * CBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

normal phenotype

no abnormal phenotype detected ( J:156541 )

• viable and fertile with no morphological abnormalities

Genotype
MGI:4422182

cn2

• Allelic Composition: Stk3^tm1.1Yy/Stk3^tm1Yy; Stk4^tm1.1Yy/Stk4^tm1.1Yy
• Genetic Background: involves: C57BL/6 * CBA

mortality/aging

decreased susceptibility to induced morbidity/mortality ( J:156541 )

• following adenoviral cre injection mice are completely protected from TNF alpha or Jo-2 antibody (a Fas agonist) induced mortality

liver/biliary system

abnormal liver physiology ( J:156541 )

• following adenoviral cre injection mice are completely protected from TNF alpha induced liver damage

decreased hepatocyte apoptosis ( J:156541 )

• following adenoviral cre injection mice are protected from TNF alpha or Jo-2 antibody (a Fas agonist) induced apoptosis

homeostasis/metabolism

decreased circulating alanine transaminase level ( J:156541 )

• following adenoviral cre injection mice are protected from TNF alpha induced increases in ALT levels

decreased circulating aspartate transaminase level ( J:156541 )

• following adenoviral cre injection mice are protected from TNF alpha induced increases in ALT levels

abnormal response/metabolism to endogenous compounds ( J:156541 )

• following adenoviral cre injection mice are protected from TNF alpha induced liver damage

cellular

decreased hepatocyte apoptosis ( J:156541 )

• following adenoviral cre injection mice are protected from TNF alpha or Jo-2 antibody (a Fas agonist) induced apoptosis

Genotype
MGI:4422186

cn3

• Allelic Composition: Stk3^tm1.1Yy/Stk3^tm1Yy; Stk4^tm1.1Yy/Stk4^tm1.1Yy; Tg(CAG-cre/Esr1*)5Amc/0
• Genetic Background: involves: C57BL/6 * CBA

liver/biliary system

increased hepatocyte proliferation ( J:156541 )

enlarged liver ( J:156541 )

• at 1 - 7 months after tamoxifen treatment

increased liver tumor incidence ( J:156541 )

• some mice treated with tamoxifen at birth develop cholangiocarcinomas composed of mainly multilayered biliary epithelial cells

increased hepatocellular carcinoma incidence ( J:156541 )

• all mice treated with tamoxifen at birth develop tumors which display characteristics of hepatocellular carcinoma by 6 months of age

neoplasm

increased liver tumor incidence ( J:156541 )

• some mice treated with tamoxifen at birth develop cholangiocarcinomas composed of mainly multilayered biliary epithelial cells

increased hepatocellular carcinoma incidence ( J:156541 )

• all mice treated with tamoxifen at birth develop tumors which display characteristics of hepatocellular carcinoma by 6 months of age

increased carcinoma incidence ( J:156541 )

• some mice treated with tamoxifen at birth develop cholangiocarcinomas composed of mainly multilayered biliary epithelial cells

cardiovascular system

enlarged heart ( J:156541 )

• in some mice at 1 - 7 months after tamoxifen treatment

digestive/alimentary system

enlarged stomach ( J:156541 )

• at 1 - 7 months after tamoxifen treatment

hematopoietic system

enlarged spleen ( J:156541 )

• in some mice at 1 - 7 months after tamoxifen treatment

immune system

enlarged spleen ( J:156541 )

• in some mice at 1 - 7 months after tamoxifen treatment

cellular

increased hepatocyte proliferation ( J:156541 )

growth/size/body

enlarged heart ( J:156541 )

• in some mice at 1 - 7 months after tamoxifen treatment

enlarged liver ( J:156541 )

• at 1 - 7 months after tamoxifen treatment

enlarged spleen ( J:156541 )

• in some mice at 1 - 7 months after tamoxifen treatment

Genotype
MGI:4422187

cn4

• Allelic Composition: Stk3^tm1.1Yy/Stk3^tm1Yy; Stk4^tm1.1Yy/Stk4^tm1.1Yy; Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺
• Genetic Background: involves: C57BL/6 * CBA * DBA

liver/biliary system

increased hepatocyte apoptosis ( J:156541 )

• slight

increased hepatocyte proliferation ( J:156541 )

abnormal liver morphology ( J:156541 )

• dysplasia at 1 month of age

• increase in hepatocyte cell density

enlarged liver ( J:156541 )

• at 1 month of age

abnormal hepatocyte morphology ( J:156541 )

• smaller

• some cells have vacuolated cytoplasm

cellular

increased hepatocyte apoptosis ( J:156541 )

• slight

increased hepatocyte proliferation ( J:156541 )

growth/size/body

enlarged liver ( J:156541 )

• at 1 month of age

Genotype
MGI:4422181

cn5

• Allelic Composition: Stk3^tm1Yy/Stk3^tm1.1Yy; Stk4^tm1.1Yy/Stk4^tm1.1Yy; Tg(Prrx1-cre)1Cjt/0
• Genetic Background: involves: C57BL/6 * CBA * SJL

limbs/digits/tail

abnormal limb bone morphology ( J:156541 )

• shorter skeletal elements in the limbs

short limbs ( J:156541 )

skeleton

abnormal limb bone morphology ( J:156541 )

• shorter skeletal elements in the limbs

decreased length of long bones ( J:156541 )

abnormal cartilage morphology ( J:156541 )

• cell size appears smaller and cell density is increased in the limb cartilage

abnormal long bone hypertrophic chondrocyte zone ( J:156541 )

• proliferating cells are detected in the hypertrophic zone

• apoptosis is decreased compared to controls

• despite the increase in proliferation and decrease in apoptosis cartilage size is not increased

abnormal skeleton physiology ( J:156541 )

• increase in proliferation of cells in the developing limb

Genotype
MGI:4422180

cx6

• Allelic Composition: Stk3^tm1.1Yy/Stk3^tm1.1Yy; Stk4^tm1.1Yy/Stk4^tm1.1Yy
• Genetic Background: involves: C57BL/6 * CBA

mortality/aging

embryonic lethality during organogenesis, complete penetrance ( J:156541 )

• die between E9.5 and E11.5

embryo

abnormal embryo development ( J:156541 )

• multiple developmental defects at E9.5 - E10.5

embryonic growth retardation ( J:156541 )

• at E9.5-E10.5

cellular

decreased fibroblast apoptosis ( J:156541 )

• MEFs are resistant to TNF alpha induced apoptosis

decreased hepatocyte apoptosis ( J:156541 )

• resistant to TNF alpha induced apoptosis

liver/biliary system

decreased hepatocyte apoptosis ( J:156541 )

• resistant to TNF alpha induced apoptosis

growth/size/body

embryonic growth retardation ( J:156541 )

• at E9.5-E10.5

Genotype
MGI:4422183

cx7

• Allelic Composition: Stk3^tm1.1Yy/Stk3^tm1Yy; Stk4^tm1.1Yy/Stk4^tm1.1Yy
• Genetic Background: involves: C57BL/6 * CBA

neoplasm

increased liver tumor incidence ( J:156541 )

• at 12 months of age tumors develop in 2 of 31 mice

homeostasis/metabolism

increased circulating alanine transaminase level ( J:156541 )

• in untreated mice

increased circulating aspartate transaminase level ( J:156541 )

• in untreated mice

liver/biliary system

increased liver tumor incidence ( J:156541 )

• at 12 months of age tumors develop in 2 of 31 mice

Genotype
MGI:4422185

cx8

• Allelic Composition: Stk3^tm1.1Yy/Stk3⁺; Stk4^tm1.1Yy/Stk4^tm1.1Yy
• Genetic Background: involves: C57BL/6 * CBA

mortality/aging

decreased susceptibility to induced morbidity/mortality ( J:156541 )

• following adenoviral cre injection mice are protected from TNF alpha or Jo-2 antibody (a Fas agonist) induced mortality

liver/biliary system

abnormal liver physiology ( J:156541 )

• following adenoviral cre injection mice are protected from TNF alpha induced liver damage

decreased hepatocyte apoptosis ( J:156541 )

• following adenoviral cre injection mice are protected from TNF alpha or Jo-2 antibody (a Fas agonist) induced apoptosis

homeostasis/metabolism

decreased circulating alanine transaminase level ( J:156541 )

• following adenoviral cre injection mice are mostly protected from TNF alpha induced increases in ALT levels

decreased circulating aspartate transaminase level ( J:156541 )

• following adenoviral cre injection mice are mostly protected from TNF alpha induced increases in ALT levels

abnormal response/metabolism to endogenous compounds ( J:156541 )

• following adenoviral cre injection mice are protected from TNF alpha induced liver damage

cellular

decreased hepatocyte apoptosis ( J:156541 )

• following adenoviral cre injection mice are protected from TNF alpha or Jo-2 antibody (a Fas agonist) induced apoptosis